| Detected | Trial | Change |
|---|---|---|
| 2026-06-12 | NCT07391774 Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed… |
Trial sites expanded: 14 -> 18 locations |
| 2026-06-09 | NCT05870579 [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+… |
overall status: "Active Not Recruiting" → "Recruiting" |
| 2026-06-09 | NCT05870579 [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+… |
Trial sites expanded: 13 -> 25 locations |
| 2026-06-06 | NCT07391774 Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed… |
Recruitment opened |
| 2026-06-06 | NCT07391774 Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed… |
Trial sites expanded: 0 -> 14 locations |
| 2026-06-06 | NCT06377852 The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study |
Trial sites expanded: 67 -> 73 locations |
| 2026-06-05 | NCT05870579 [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+… |
overall status: "Recruiting" → "Active Not Recruiting" |
| 2026-06-05 | NCT05870579 [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+… |
Trial sites reduced: 25 -> 13 locations |
| 2026-06-05 | NCT07174336 A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in… |
Trial sites expanded: 324 -> 327 locations |
| 2026-06-04 | NCT07492641 BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or… |
Trial sites expanded: 4 -> 13 locations |
| 2026-06-03 | NCT05827081 Phase IIIb Study of Ribociclib + ET in Early Breast Cancer |
Trial sites expanded: 207 -> 215 locations |
| 2026-05-28 | NCT05870579 [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+… |
date change Completion pushed: 2032-01-26 -> 2032-04-05 |
| 2026-05-23 | NCT07492641 BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or… |
Recruitment opened |
| 2026-05-23 | NCT07492641 BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or… |
Trial sites expanded: 0 -> 4 locations |
| 2026-05-20 | NCT06760637 Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast… |
overall status: "Recruiting" → "Active Not Recruiting" |
| 2026-05-20 | NCT06760637 Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast… |
Trial sites reduced: 518 -> 463 locations |
| 2026-05-19 | NCT07405801 A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus… |
Trial sites expanded: 19 -> 36 locations |
| 2026-05-16 | NCT07085767 Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2… |
Trial sites expanded: 85 -> 124 locations |
| 2026-05-15 | NCT07174336 A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in… |
Trial sites expanded: 317 -> 323 locations |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT05161195 | Roll-over Study to Allow Continued Access to Ribociclib | Metastatic Breast Cancer | Active, Not Recruiting |
| Phase 3 | |||
| NCT06380751 | Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine… | Advanced Breast Cancer | Recruiting |
| NCT07085767 | Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2… | Breast Cancer | Recruiting |
| NCT04862663 | Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer… | Locally Advanced (Inoperable) or Metastatic Breast Cancer | Recruiting |
| NCT07492641 | BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or… | HR+/HER2- Breast Cancer | Recruiting |
| NCT06065748 | A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a… | Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer | Recruiting |
| NCT07174336 | A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in… | Breast Neoplasms | Recruiting |
| NCT06377852 | The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study | Metastatic Breast Cancer | Recruiting |
| NCT05827081 | Phase IIIb Study of Ribociclib + ET in Early Breast Cancer | Early Breast Cancer | Recruiting |
| NCT07391774 | Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed… | Anatomic Stage II Breast Cancer AJCC v8 | Recruiting |
| NCT03701334 | A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant… | Early Breast Cancer | Active, Not Recruiting |
| NCT04964934 | Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m… | ER-Positive HER2-Negative Breast Cancer | Active, Not Recruiting |
| NCT04055493 | Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in… | Breast Cancer Female | Active, Not Recruiting |
| NCT06760637 | Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast… | Breast Cancer | Active, Not Recruiting |
| Phase 2 | |||
| NCT05467891 | Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent… | Locoregional Recurrence | Recruiting |
| NCT04116541 | A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular… | Malignant Solid Tumor | Recruiting |
| NCT07405801 | A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus… | Breast Cancer | Recruiting |
| NCT06953882 | Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative… | HER2 Negative Breast Cancer | Recruiting |
| NCT07054190 | A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated… | Breast Cancer | Recruiting |
| NCT05843253 | Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG… | High Grade Glioma | Recruiting |
| NCT07195227 | Efficacy and Safety of Camizestrant Plus Ribociclib in Patients With Breast Cancer | Hormon Receptor Positive Breast Cancer | Recruiting |
| NCT02712723 | Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive… | Breast Cancer | Active, Not Recruiting |
| NCT04417621 | Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated… | Melanoma | Active, Not Recruiting |
| NCT02934568 | Ribociclib (LEE011) Rollover Study for Continued Access | Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies | Active, Not Recruiting |
| NCT05296746 | Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast… | Breast Cancer Stage II | Active, Not Recruiting |